The ability to culture CD34 + stem cells, while maintaining their pluripotency, is essential for manipulations such as gene transfection for therapeutic trials.
+ stem cells with modified genetic material is rapidly becoming an area of intense interest for both future and on-going therapeutic trials in humans. Although the mode of gene delivery has been diverse, hematopoietic stem cell studies have primarily used either retroviral or adenoviral vectors. [1] [2] [3] [4] [5] Overall, there has been low stem cell transduction efficiency and some controversy as to the safety when using these vectors. For many current modes of gene transfer (with the exception of adenoviral and lentiviral systems), cell division is required. Previous studies have demonstrated that electroporation can be a reasonable means of hematopoietic cell gene transfer, and the genes delivered are integrated into the host chromosome. [6] [7] [8] [9] [10] Although cell synchronization and electroporation studies have led to controversial conclusions on the requirement for S-phase, [11] [12] [13] it appears that efficient electroporation of hematopoietic cells requires prestimulation, which results in an apparent increase in the S-phase sub-population. 6, 14, 15 Ideal culture conditions would promote a high efficiency of gene transfer to ensure not only short-term, but also long-term engraftment and subsequent bone marrow repopulation with each hematopoietic lineage carrying the transgene. In vitro manipulation of human stem cells for gene transfer by electroporation involves three primary goals: (1) optimization of short-term culture conditions that will increase the percentage of cells in S-phase and enhance successful incorporation of exogenous gene delivered; (2) maintenance of the pluripotent stem cells for full bone marrow engraftment and long-term reconstitution after transplant; and (3) optimization of the electroporation conditions for efficient transfection. It has been shown that many culture conditions will support stem cell division. However, this usually leads to loss of pluripotency and diminished short-term and/or long-term reconstituting ability as a consequence of expansion and differentiation.
Optimal ex vivo culture conditions and/or recombinant growth factor combinations that will promote survival, proliferation, and self-renewal of the most primitive CD34 + stem cell, yet prevent differentiation into committed progenitors are being explored. [18] [19] [20] [21] Various studies have been performed using numerous combinations of early-acting cytokines that affect post-G0 phase exit, and initiation of cell-cycling. These include thrombopoietin (TPO), stem cell factor (SCF), Flt-3 ligand (Flt-3L), interleukin-3 (IL-3), IL-12, IL-6, IL-1 and granulocyte-macrophage colonystimulating factor (GM-CSF), as well as late-acting cytokines (affecting proliferation and maturation) such as erythropoietin (EPO), G-CSF, and TGF-beta. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] The differences between early-and late-acting cytokines are often complicated by the fact that the effects of an individual cytokine in combination with others can be multiple, depending on the stage of differentiation of a particular stem cell. 32, 33 In addition to recombinant cytokines, the role of stromal contact, 17, [34] [35] [36] stroma-conditioned media, 37 fibronectin 35 and the use of endothelial layers 38 to maintain stem cells in a primitive state has been evaluated. Among the most frequently used cytokine combinations, studies have consistently shown that TPO in various cocktails with the tyrosine kinase receptor ligands, Flt-3L and SCF, is capable of maintaining phenotypic self-renewal of primitive stem cells. 22, 25, [39] [40] [41] Numerous studies have shown that IL-3 has an important role in survival 42 and ex vivo expansion of primitive cells. 25, 43 We chose to study culture conditions that would maintain the primitive state of stem cells yet maximize the proportion of CD34
+ cells in S-phase in order to determine the optimal time for gene transfer by electroporation. Our goal was to maintain CD34 pluripotency and optimize the culture conditions for electroporation using enhanced green fluorescence protein (EGFP) as a reporter gene. The effect of culturing CD34
+ cells with TPO, Flt-3L, and SCF, with or without IL-3 and PIXY321 (GM-CSF/IL-3 fusion protein) in addition to other combinations of recombinant cytokines was explored. We also studied the effect of stroma-conditioned media and human serum on the transfection efficiency in CD34
+ cells. The cell-cycle (%S-phase cells), EGFP expression in CD34 + cells, colonyforming units (CFU), and long-term culture-initiating cells (LTC-IC) were used to determine optimal reporter gene delivery with electroporation.
Materials and methods

Materials
The HPCA-2 monoclonal antibody (anti-CD34 PE or APC), CD38 PE, CD117 (c-kit) PE and HLA-DR FITC were from Becton Dickinson (San Jose, CA, USA). Thy-1 monoclonal antibody (anti-CD90 PE) was from PharMingen (San Diego, CA, USA). Enhanced green fluorescence protein (EGFP) used in this study is encoded on the plasmid pEGFP-N1 (ClonTech Laboratories, Palo Alto, CA, USA). The control plasmid pcDNA3 was from Invitrogen (Carlsbad, CA, USA). The ECM 600 Electroporation System (an exponential decay electroporator) was from Genetronics (San Diego, CA, USA 
CD34
+ cell selection
Fresh or cryopreserved peripheral blood apheresis products from non-cancerous donors or ovarian and breast cancer patients, treated with prior chemotherapy and/or recombinant granulocyte colony-stimulating factor (G-CSF), were used as the source of cells for CD34 + cell selection. Peripheral blood apheresis mononuclear cells were resuspended at a final concentration of 2 × 10 7 cells/ml in selection buffer (0.4% sodium citrate, 1% HSA in D-PBS) supplemented with 0.5% human immunoglobulin solution and incubated for 15 min at room temperature. CD34 selection reagents were obtained from Baxter Healthcare and used as described by the manufacturer. Anti-CD34 monoclonal antibody (9C5, mouse IgG1) was added at 0.5 g/10 6 cells and the cells were mixed by end-over-end rotation for 30 min at room temperature. The cells were then washed twice by centrifugation for 10 min at 250 g and resuspended at 2 × 10 7 cells/ml in selection buffer. Paramagnetic beads coated with sheep anti-mouse IgG1 were added to the cell suspension at a cell:bead ratio of 1:1 and rotated for 30 min at room temperature. The bead-cell complexes were isolated using a magnetic tube holder and washed twice with selection buffer. CD34
+ cells were released from the magnetic beads by addition of 1:5 dilution of CD34 peptide release agent diluted in selection buffer, followed by an end-over-end rotation for 30 min at room temperature. The beads were then removed on the magnet and the released CD34 + cells were isolated in selection buffer. CD34 + purity was evaluated by flow cytometry using anti-CD34-PE (HPCA-2). The Miltenyi CD34 isolation kit, MidiMacs, and SuperMacs separation columns were also used according to the manufacturer's instructions. CD34
+ cell purities were more than 90% as assessed by flow cytometry after selection.
Culture conditions for CD34
+ cells CD34 + cells were cultured in tissue culture flasks at 5 × 10 5 cells/ml in X-VIVO 10 serum-free cell culture medium supplemented with 2 mm of fresh l-glutamine. The culture medium was supplemented with various combinations of recombinant human growth factors including: 20 ng/ml IL-3, 40 ng/ml IL-6, 50 ng/ml Flt-3L, 20 ng/ml stem cell factor (SCF), and 50 ng/ml TPO. Some cultures received 20 ng/ml PIXY 321 (IL-3/GM-CSF fusion protein) or 10% pooled human AB serum. Additional cultures were supplemented with 20% stroma-conditioned medium (CM) prepared from confluent monolayers of allogeneic bone marrow. Stromaconditioned medium was prepared from bone marrow mononuclear cells isolated (from 5 to 10 ml) over a Ficoll gradient and plated in 75 cm 2 flasks supplemented with 20 mls of MyeloCult H5100. Confluent stromal monolayers were formed after 1 month of culture. CM was prepared by removing the stroma culture medium (containing serum), rinsing once with D-PBS, and replacing it with X-VIVO 10 serum-free culture medium. The flasks were incubated for an additional 7 days. CM was removed and filtered through a 0.2 m filter and supplemented into fresh X-VIVO 10 at a final concentration of 20% (v/v) containing recombinant growth factors.
CD34 mean fluorescence intensity and subset analysis
Freshly isolated CD34
+ cells and cultured CD34 + cells were analyzed for CD34 mean fluorescence intensity (MFI) on day 0, 1, 2, 3 and 4 on a FACScan or FACScalibur flow cytometer. The cells were washed 1 × in PBS supplemented with 0.5% BSA and then incubated with 20 l of HPCA-2 monoclonal antibody (anti-CD34 PE) for 30 min on ice. After incubation, the cells were washed 1 × and resuspended in 0.5-1.0 ml of PBS supplemented with 0.5% BSA. Propidium iodide was added at 10 g/ml to each tube containing CD34
+ cells immediately prior to flow acquisition to exclude non-viable cells during analysis. The MFI of CD34 + PE cells (FL2) was determined for gated viable cells (propidium iodide negative) on a dot plot displaying FL1 (x-axis) vs FL2 (y-axis). CD34 subset analysis was done on days 0, 2, and 4 of culture. CD34 subset labeling was done using anti-CD34 APC in combination with CD38, HLA-DR, c-kit, or Thy-1 PE, while gating on viable cells.
Cell cycle analysis using propidium iodide
Freshly isolated CD34
+ cells and cultured CD34 + cells were analyzed for stages of cell cycling (G0/G1, S-phase, and G2/M) with propidium iodide on days 0, 1, 2, 3 and 4 using a FACScan flow cytometer. Approximately 5 × 10 5 cells were centrifuged at high speed for 5-10 min. The pellet was resuspended in 1 ml of hypotonic propidium iodide solution prepared in 100 ml sterile water containing 0.1 g Na citrate, 5 mg propidium iodide, 0.1 ml Triton X-100 and 10 mg boiled RNAse A. The cells were incubated on ice for 20-60 min until analysis. The G0/G1 peak was set at channel 400 (FL-2 A) and on channel 200 (FL-3 H) as displayed on a histogram. FL-2 A (linear) was used for the analysis and cell cycle determination using ModFIT-LT. A Bone Marrow Transplantation minimum of 50 000 events was acquired on a FACScan flow cytometer and analyzed using CellQuest.
Electroporation
Electroporation efficiency determination was performed as previously described. 6 Immediately after electroporation, the CD34 + cells were resuspended in cell culture medium containing TPO/SCF/Flt-3L with or without IL-3, PIXY321, CM, and serum in 24-well plates at 1 × 10 6 cells/well. The cells were incubated at 37°C and 5% CO 2 for an additional 48 h prior to transfection efficiency and viability analyses by flow cytometry.
Colony-forming unit (CFU) assay
CD34
+ cells after 0, 1, 2, 3 and 4 days in culture were plated in CFU assays. Each time point was evaluated in duplicate by plating 5000 cells per 35 mm dish in 1 ml of MethoCult H4433 (PHA/LCM with erythropoietin). The CFU assays were scored after 14 days incubation at 37°C, 5% CO 2 for colony-forming unit granulocyte-macrophage (CFU-GM), burst-forming unit erythroid (BFU-E), and mixed (CFU-Mix) colonies. Electroporated CD34 + cells, after 0, 1, 2, 3 and 4 days in culture, and 48 hours post electroporation were plated in CFU assays. The EGFPpositive colonies were scored on a Nikon inverted fluorescent microscope after 14 days in culture. The frequency of EGFP colonies is expressed as the number of EGFPpositive colonies relative to the total number of colonies.
Long-term culture-initiating cell (LTC-IC) assay
CD34
+ cells after 0, 1, 2, 3 and 4 days in culture were plated in LTC-IC assays at 1 × 10 5 cells per well on preformed irradiated (25 Gy) allogeneic bone marrow stroma in 24-well plates. Non-electroporated cells were plated at 2 × 10 4 CD34 + cells per well. Each well contained 2 ml of MyeloCult H5100 supplemented with 0.2 ng/ml of hydrocortisone. The plates were incubated at 37°C, 5% CO 2 for 5-6 weeks. At weekly intervals, half of the culture medium was replaced with fresh culture medium. At the end of the culture period, the supernatant was removed, and cells were trypsinized by rinsing with D-PBS prior to adding 200 l of 0.05% trypsin/0.53 mm EDTA solution. After 10-15 min of incubation, the trypsinized cells were combined with the culture supernatant and centrifuged at 250 g for 10 min. The total cells from each well were then plated into CFU assays as previously described and scored after 14 days. EGFP-positive colonies and cloning efficiencies were determined as described previously for the CFU assay.
Results
Effect of culture conditions on CD34 MFI, CFU and LTC-IC
The CD34 MFI and CFU frequency after a 3 day culture period are shown in Figure 1 . Cultures supplemented with TPO/SCF/Flt-3L maintained a higher frequency for both CD34 MFI and CFU compared to those with other recombinant cytokine combinations, including IL-3, IL-6 and PIXY321. This is clearly illustrated in a dot plot shown in Figure 2 , in which CD34
+ cells cultured in TPO/SCF/Flt-3L sustained the highest CD34 brightness, whereas the addition of PIXY321 or serum caused a dramatic decline in CD34 brightness during the same culture period. In addition, the colonies derived from TPO/SCF/Flt-3L cultures consisted of all types of colonies including CFU-GM, BFU-E, and CFU-Mixed, whereas colonies from those with additional serum or PIXY321 contained predominantly CFU-GM (data not shown).
The number of LTC-IC (long-term culture-initiating cells) derived from cultures containing TPO/SCF/Flt-3L was superior to those with additional serum or PIXY321 (Figure 3) . The LTC-IC frequency per 20 000 cells peaked at day 2 in cultures supplemented with TPO/SCF/Flt-3L and was higher than at day 0. In particular, the LTC-IC frequency from the TPO/SCF/Flt-3L culture was 5-fold higher than at day 0, whereas those from cultures with additional PIXY321 or serum were only 2-fold higher than at day 0. Similar to our observed CFU results, the LTC-IC colonies from the TPO/SCF/Flt-3L culture consisted of two types of colonies (CFU-GM and BFU-E) whereas those supplemented with PIXY321 or serum were all CFU-GM colonies (data not shown). As shown in Figure 3 (inset) , the CFU per 10 000 cells peaked at days 1 and 2, then dropped to the levels similar to non-stimulated cells at days 3 and 4. 
Cell cycle analysis of cultured CD34
+ cells
Using hypotonic propidium iodide, we observed 27 Ϯ 1.9% CD34 + cells in S-phase after 2 days in cultures supplemented with TPO/SCF/Flt-3L (Figure 4b ). The percentage of S-phase cells was significantly increased by the addition of PIXY321 (41.1 Ϯ 4.4%, P р 0.01) after 2 days in culture. However, PIXY321 reduced CD34 brightness and resulted in a lower number of LTC-IC at day 2 as shown in Figures 2 and 3 . The higher percentage of S-phase cells in the presence of PIXY321 was accompanied by less cells in G0 (Figure 4a , P р 0.01). No change in the percent of cells in G0-G1, S-phase and G2-M was observed when serum was supplemented into cultures with TPO/SCF/Flt-3L (Figure 4 ). There was little or no increase in total cell numbers during the 4-day culture period using TPO/SCF/Flt-3L, yet a slight increase in total cell numbers was observed when serum and PIXY321 was added. 
Effect of TPO/SCF/Flt-3L on CD34
+ subsets
To determine if a short-term culture period (4 days) in the presence of TPO/SCF/Flt-3L could sustain or expand the more primitive CD34 + cell subsets, we examined the expression of CD38, Thy-1, c-kit, and HLA-DR by flow cytometry. Figure 5 shows representative profiles for uncultured (day 0) and cultured (day 4) CD34 + cells. These results indicate that, at least by phenotype, TPO/SCF/Flt-3L exerts a differential effect on these subsets. The frequency of Thy-1 + cells after 4 days appears to be decreased whereas the CD38 Ϫ , c-kit low and HLA-DR Ϫ subpopulations have expanded. The apparent selective expansion of these primitive subsets is at least partially reflected in the increased frequency of LTC-IC after a 4-day culture period in the presence of TPO/SCF/Flt-3L. These results also suggest that this cytokine combination can induce cell cycling and therefore stable integration of exogenous DNA in the more primitive CD34 + cell subsets attributed to long-term hematopoietic reconstitution.
Transfection of CD34 + cells by electroporation
We have previously reported a correlation between electroporation efficiency and %S-phase CD34 + cells, 6 showing that 24-48 h incubation of CD34 + cells in X-VIVO 10 supplemented with TPO/SCF/Flt-3L resulted in 28% S-phase and 20% EGFP/CD34 + cells. A representative dot plot showing CD34
+ and EGFP expression 2 days post electroporation (4 days total in culture) is shown in Figure 6 . In this study, we extended our investigation on these cells by evaluating LTC-IC (Figure 7) . The peak %EGFP + /LTC-IC was observed when CD34 + cells were electroporated between days 1 and 2 of culture. The LTC-IC decline after day 3 may be due, in part, to differentiation as suggested by the decrease in CD34 MFI (Figure 7) . The decline of CD34 MFI may also explain our previous observation 6 that the transient EGFP + /CD34 + peaked at day 2 while the %S-phase was maintained at Ͼ25% for up to 4 days.
The electroporation efficiencies for cells cultured under different conditions for CD34, CFU, and LTC-IC are summarized in Table 1 that 56 Ϯ 15% of the CFU were EGFP + indicating that the committed progenitor cells were also transfected short term. Considering total cell output, for cultures supplemented with TPO/SCF/Flt-3L, the transfection efficiency was 20%, 1.8%, and 0.04% for EGFP + CD34 + cells, CFU and LTC-IC, respectively.
We attempted to further enhance the electroporation efficiency by adding IL-3 or stroma-conditioned medium to TPO/SCF/Flt-3L. The electroporation results in Table 1 show that IL-3 enhanced the EGFP + /CD34 + cells from 20 Ϯ 1% to 41 Ϯ 2%, however, the percentage of EGFP + /CFU and EGFP + /LTC-IC did not increase. The conditioned medium from two different donors gave inconsistent results with stroma-conditioned medium from donor 1 providing an enhancement of EGFP + CD34 transient expression while stroma-conditioned medium from donor 2 did not. As shown, the frequency of EGFP + /CFU and EGFP + /LTC-IC were not significantly enhanced by the addition of IL-3 or stroma-conditioned medium.
Discussion
Short-term culture of CD34
+ stem cells could provide a means for gene modification of hematopoietic cell precursors. However, there is a critical demand in maintaining the stem cell pluripotency, which is essential for stable long-term gene expression in hematopoietic lineages. In this study, we demonstrated that CD34
+ cells cultured in serum-free medium supplemented with TPO/SCF/Flt-3L for 2-4 days sustain a small loss in CD34 brightness and exhibit a 5-fold higher frequency of LTC-IC compared to day 0. We also provided evidence for expansion of the more primitive CD34
+ cells (CD38 Ϫ , c-kit low and HLA-DR Ϫ ) in this cytokine combination. Cell cycle analysis of CD34 + cells, as evaluated by flow cytometry, revealed that %S-phase cells increased from 3% at day 0 to 28% at day 2. We observed in this study that the %EGFP + /LTC-IC peaked at day 2, suggesting that the transient expression may be a good predictor of long-term transfection stability. The percentage of EGFP + /CD34 + cells and EGFP + /LTC-IC declined at days 3 and 4 of culture although the percent of cells in S-phase did not. These data suggest that S-phase may not be critical for transfection as measured by LTC-IC.
Other recombinant cytokine combinations (including IL-3) resulted in a greater loss of CD34 MFI and frequency of CFU after a 4-day culture period. IL-3 is a well known stimulatory and survival factor for early hematopoietic stem cell. 25, 42, 43 However, the addition of IL-3 to cultures containing TPO/SCF/Flt-3L, while useful for enhancing the transient expression of EGFP + CD34 + cells, did not enhance the percentage of EGFP + /LTC-IC, compared to TPO/ SCF/Flt-3L alone. Our results suggest that IL-3 can only enhance transient EGFP expression in the committed clono- + cells are apparently combinatorial, although each of the components plays its own role, yet to be defined. TPO has been shown to maintain primitive cell survival and to suppress apoptosis. 44 These effects are augmented when used in combination with other early-acting cytokines such as SCF, Flt-3L and/or c-kit ligand, leading to more effective expansion of primitive cells ex vivo. 39, 43, 45, 46 Flt-3L has a direct effect on hematopoietic cells, is synergistic with other growth factors, and the addition of Flt-3L in cultures has been shown to increase the yield of primitive cells. 25, [47] [48] [49] Flt-3L was also shown to recruit more CD34 + /CD38 Ϫ cells into division and enhance retroviral transduction of the expanded cells. 41 SCF has been demonstrated to promote the viability of progenitor cells in culture and may promote the cycling of G0-CD34 + cells. 22 + cells using TPO/Flt-3L. CFU-GM were expanded 2 × 10 6 -fold over the initial number after 6 months in culture. In their studies, the addition of SCF reduced the number of LTC-IC while the addition of IL-3 completely depleted LTC-IC after only 2 weeks. Our studies show the addition of IL-3 had no effect on LTC-IC cells.
High efficiency EGFP reporter gene transfection by electroporation has recently been reported with bone marrow CD34 + cells 15 and with dendritic cells (DC) derived from cultured CD34 + cells. 14 In comparison, CD34-derived DC had a 16% transfection efficiency in contrast to monocytederived DC (Ͻ2%). Murray et al 46 used retroviral transduction and cycling CD34 + Thy-1 + cells to predict a 6-fold improvement in the transduction efficiency with a shortterm culture using TPO/SCF/Flt-3L compared to IL-3, IL-6, and leukemia inhibitory factor (LIF). It has been Bone Marrow Transplantation reported by several investigators that CD34 bright cells are responsible for more long-term stable hematopoiesis while the CD34 dim cells are more differentiated and less likely to provide long-term stable hematopoiesis. [53] [54] [55] [56] It has been shown that short-term culture periods (2-6 days) in serumfree or serum-reduced conditions can increase the SCIDrepopulating cell frequency and enhance the efficiency of EGFP reporter genes in repopulating NOD/SCID mice. 16, 57, 58 Considering our results, we conclude that shortterm culture of CD34 + cells with TPO/SCF/Flt-3L alone can increase the percentage of cycling CD34
+ cells resulting in enhanced expression of EGFP reporter genes by electroporation.
